Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 1/2 1

Status

Completed 5

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 2Tumor-Agnostic 1Gastrointestinal 1

Conditions

Pleural Effusion 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Lung Neoplasms 1Advanced Solid Tumors 1

Interventions

Cisplatin 3202Cyclophosphamide 3195Carboplatin 2977Radiotherapy 2790Paclitaxel 2718Gemcitabine 2572pembrolizumab 2385Bevacizumab 2209Docetaxel 2199Fluorouracil 1851Capecitabine 1833Oxaliplatin 1742Dexamethasone 1605Nivolumab 1581Doxorubicin 1501Rituximab 1488Magnetic Resonance Spectroscopy 1387Etoposide 1346Irinotecan 1248Leucovorin 1226Drug Therapy 1205Cytarabine 1130Pemetrexed 1076fludarabine 1063Specimen Handling 1017Vincristine 964Cetuximab 945Trastuzumab 945Prednisone 942Lenalidomide 937

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Cdc25C phosphatase (211-221) × Clear all
NCT04953962 2023-08-15

Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer

CanBas Co. Ltd.

Phase 2 Completed
36 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT00700336 2021-07-20

Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)

CanBas Co. Ltd.

Phase 1/2 Completed
69 enrolled 9 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT03113188 2021-03-10

CBP501, Cisplatin and Nivolumab in Advanced Refractory Tumors

CanBas Co. Ltd.

Phase 1 Completed
47 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT00942825 2017-05-24

CBP08-02

CanBas Co. Ltd.

Phase 2 Completed
195 enrolled 8 charts
Thoracic

Lung Neoplasms, Neoplasm Metastasis, Pleural Effusion

NCT00551512 2017-03-14

Phase I Study of CBP501 and Cisplatin in Patients With Advanced Refractory Solid Tumors

CanBas Co. Ltd.

Phase 1 Completed
48 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡